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Bjarni Ásgeirsson a,*,1, Sigurbjörn Markússon a, Sigríður S. Hlynsdóttir a, Ronny Helland b, 
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A B S T R A C T   
Background: Para-nitrophenyl phosphate, the common substrate for alkaline phosphatase (AP), is available as a 
cyclohexylamine salt. Here, we report that cyclohexylamine is a non-competitive inhibitor of APs. 
Methods: Cyclohexylamine inhibited four different APs. Co-crystallization with the cold-active Vibrio AP (VAP) 
was performed and the structure solved. 
Results: Inhibition of VAP fitted a non-competitive kinetic model (Km unchanged, Vmax reduced) with IC50 45.3 
mM at the pH optimum 9.8, not sensitive to 0.5 M NaCl, and IC50 27.9 mM at pH 8.0, where the addition of 0.5 M 
NaCl altered the inhibition to the level observed at pH 9.8. APs from E. coli and calf intestines were less sensitive 
to cyclohexylamine, whereas an Antarctic bacterial AP was similar to VAP in this respect. X-ray crystallography 
at 2.3 Å showed two binding sites, one in the active site channel and another at the surface close to dimer 
interface. Antarctic bacterial AP and VAP have Trp274 in common in their active-sites, that takes part in binding 
cyclohexylamine. VAP variants W274A, W274K, and W274H gave IC50 values of 179 mM, 188 mM and 187 mM, 
respectively, at pH 9.8. 
Conclusions: The binding of cyclohexylamine in locations at the dimeric interface and/or in the active site of APs 
may delay product release or reduce the rate of catalytic step(s) involving conformational changes and inter-
subunit communications. 
General significance: Cyclohexylamine is a common chemical in industries and used as a counterion in substrates 
for alkaline phosphatase, a clinically important and common enzyme in the biosphere.   
1. Introduction 
Alkaline phosphatases (APs; EC 3.1.3.1) are relatively nonspecific 
enzymes and work as ectoenzymes, either attached to the surface of 
animal cells, or they are excreted into the periplasmic space of bacteria 
[1]. In mammals, APs have an important role in bone formation and in 
preventing intestinal inflammation [2–7]. Recent evidence suggests that 
intestinal AP plays a role in determining which bacteria colonize the gut 
[3]. APs have also been linked with cardiovascular diseases [8–11] and 
Alzheimer disease [12–14], not all of which is well defined [15–18]. In 
bacteria, APs are believed to have the main role of harvesting nutrients 
in the form of inorganic phosphate under conditions of phosphate 
starvation [1,19]. APs hydrolyze phosphate ions from various organic 
phosphomonoesters such as glucose phosphate, lipid phosphatidates, as 
well as polyphosphates such as dinucleotides, trinucleotides and pyro-
phosphate [16,18]. In addition, AP dephosphorylates some proteins [14, 
20,21], and is used as a tool to dephosphorylate termini of poly-
nucleotides in molecular biology laboratories. Finally, AP has impor-
tance in environmental terms as an active ingredient in soil [22,23]. 
Enzyme inhibitors are useful as therapeutic agents and as tools for 
studying mechanisms of enzymatic catalysis. The potential therapeutic 
benefits associated with inhibition of APs would suggest value in char-
acterizing new AP inhibitors [24]. Many different types of compounds 
have previously been shown to act as inhibitors for APs due to the 
relatively non-specific binding-pocket in these enzymes (2–3000 entries 
in the ChEMBL database). In addition to some inorganic ions, many 
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organic compounds act as non-competitive or uncompetitive inhibitors 
for APs, including some amino acids [25,26]. The diversity in the mode 
of action of different inhibitors is also reflective of the spatial accom-
modation and catalytic environment in the active site of APs, including 
three metal ions and a serine nucleophile that can take part in binding 
and partial reactions. Inorganic phosphate, being the reaction product, 
and ions that resemble phosphate, act reversibly as competitive in-
hibitors. The inhibition can also be irreversible. One example is the 
inhibitory effect of the bactericidal molecule imipenem on the Vibrio AP 
variant (VAP) under study here [27]. Several compounds have been 
developed as potential preventive medication for abnormal calcification 
and mineral depositions in humans due to hyperactivity of tissue 
nonspecific AP or intestinal AP. A recent example is the inhibition of 
human tissue nonspecific AP by tricyclic coumarin sulphonate de-
rivatives and nicotinamide derivatives (SBI-425) where the latter has 
higher bioavailability [28,29]. 
Cyclohexylamine is a weak base, miscible with water, that is used in 
industries for the manufacturing of insecticides, antiseptics, and plasti-
cizers, and is a source of environmental pollution [22]. It is also used as a 
counterion in some commercial preparations of the much-used 
non-specific phosphatase substrate p-nitrophenyl phosphate (pNPP). 
While studying the effects of other inhibitors on VAP by using higher 
concentrations of the common p-nitrophenyl phosphate substrate than 
previously used [30,31], we observed inhibition, that turned out to be 
due to the counterion in the substrate salt. What follows is a structural 
characterization of this inhibition by cyclohexylamine. Neither the ef-
fect of cyclohexylamine on the enzymatic activity of APs nor the crystal 
structure showing the binding modes have been reported before. 
2. Materials and methods 
2.1. Materials 
Chemicals were purchased form Sigma-Aldrich (Schnelldorf, Ger-
many) or Merck (Darmstadt, Germany) including both the disodium salt 
hexahydrate of p-nitrophenyl phosphate (4876) and 4-nitrophenyl 
phosphate bis(cyclohexylammonium) salt (N3129). Alkaline phospha-
tases from E. coli (P5931) and calf intestines (79390) were purchased 
from Sigma-Aldrich. Antarctic phosphatase (M0289S) was purchased 
from New England Biolabs. Vibrio alkaline phosphatase (VAP) was pu-
rified as previously described [32]. VAP variants were produced as 
previously described [33,34]. Hanging drop vapor diffusion plates 
(VDX24 without sealant), Polyethylene glycol (PEG) and other materials 
for protein crystallization were purchased from Molecular Dimensions 
(UK) and Hampton Research (USA). 
2.2. Activity measurements 
Enzyme activity was generally measured in 100 mM Caps, 1 mM 
MgCl2, pH 9.8 at 10 ◦C over a 30 s period using a Peltier temperature- 
regulated Evolution 220 spectrophotometer (ThermoFisher). For 
comparative assays with other APs, kinetic measurements were per-
formed at 25 ◦C. At 10 ◦C, the cuvettes were pre-chilled on ice to prevent 
fogging. Two salts of p-nitrophenyl phosphate (pNPP) were used as 
specified, pNPP bis(cyclohexylamine) or pNPP disodium. The formation 
of p-nitrophenol was followed at 405 nm and quantified using an 
extinction coefficient of 18.5 mM− 1cm− 1. For exact initial substrate 
concentrations, the samples were fully hydrolyzed overnight, the 
absorbance at 405 nm measured and the initial concentrations calcu-
lated. Activity of VAP was also measured at pH 8.0 in Tris buffer (100 
mM Tris, 1 mM MgCl2, pH 8.0). 
2.3. Cyclohexylamine inhibition experiments using VAP 
Data for Lineweaver-Burk plots were obtained either at pH 9.8 (100 
mM Caps, 1 mM MgCl2) or at pH 8.0 (100 mM Tris, 1 mM MgCl2) with 
temperature regulated at 10 ◦C. At pH 9.8, pNPP disodium at 0.0–1.0 
mM was used as a substrate and cyclohexylamine was added from a 1.73 
M stock solution prepared by diluting pure cyclohexylamine 1:4 water 
and pre-adjusting the pH to the assay conditions with 6.0 M HCl). 
Cyclohexylamine was included in the assay medium at the appropriate 
concentration. GraphPad Prism® was used to analyze the data as a non- 
competitive inhibition. The inhibition mechanism was also evaluated 
using a mixed inhibition model, where the data was fitted globally in 











If the α constant = 1, the inhibition is non-competitive in nature. 
Then, the inhibitor displays equal affinity for both the free enzyme and 
the ES complex. If α < 1, then the inhibitor binds with greater affinity to 
the ES complex than the free enzyme (uncompetitive inhibition). If α >
1, then the inhibitor prefers binding to the free enzyme (uncompetitive 
inhibition) [35]. 
For evaluation of the inhibitor’s potency, standard enzyme activity 
was measured in the presence of increasing cyclohexylamine concen-
tration, ranging from 0 to 400 mM, with a constant 2 mM pNPP diso-
dium concentration. At pH 9.8, 0.5 M NaCl was added to the buffers to 
counteract ionic activation of the enzyme (due to titration of cyclo-
hexylamine with HCl) which plateaus at 0.5 M. At pH 8.0, the activity of 
the enzyme is even more dependent on ionic strength (activity plateaus 
when NaCl is above 1.0 M). Therefore, the activation due to ionic 
strength (chloride) was corrected at pH 8.0 using the equation: 
vcorrected = vapp
/
(1+ 4.010 * x / (0.2169+ x)) (2)  
where vcorrected is the corrected activity, vapp the obtained activity, and x 
is the concentration of chloride. This equation is derived from a hy-
perbolic fit measured previously under identical conditions with various 
concentration of NaCl [36]. 
A relative IC50 value was determined at 50% of the maximum inhi-
bition [37]. We obtained Ki-values using the relationship Ki = IC50 that 
holds for non-competitive inhibition [38]. 
For evaluation of reversibility of inhibition, enzyme samples were 
incubated with 50 mM cyclohexylamine for 10 min on ice in 100 mM 
Caps at pH 9.8 with 1 mM MgCl2 and 0.5 M NaCl added. Enzyme activity 
was then measured with or without cyclohexylamine (50 mM) added to 
the Caps reaction buffer containing 2 mM pNPP disodium. Ten μl of 
enzyme were added to 990 μL of reaction buffer to initiate the enzyme 
reaction, effectively diluting the inhibitor concentration from 50 to 0.5 
mM as a carry-over in the control. This concentration would be too low 
to affect enzyme activity. 
2.4. X-ray crystallography 
A Phoenix crystallization robot (Art Robbins Instruments) was used 
to screen for crystallization conditions by the sitting drop vapor diffu-
sion method. Crystallization conditions containing NaCl and PEG3350 
and buffered around neutral pH were designed using FORMULATRIX®. 
The initial screen gave three hits, which were fully optimized before 
attempting co-crystallization with cyclohexylamine. 
In order to produce cyclohexylamine bound VAP crystals, a 15 mg/ 
mL VAP solution was mixed with 2.0 M cyclohexylamine (pre-titrated to 
pH 8.0) to a final concentration of 10 mg/mL, the final ligand concen-
tration being 200 mM (around 5-fold Km). The solution was left on ice 
for an hour before use in co-crystallization experiments to allow for 
sufficient ligand binding. Original crystallization experiments proved to 
be unsuccessful due to the increased solubility of the protein upon 
addition of the ligand solution. The lack of nucleation was addressed by 
micro-seeding. The ligand bound VAP crystals were grown under 0.5 M 
NaCl, 22% (w/v) PEG3350 and 0.1 M Tris pH 7.0 in 2 μL drops 
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consisting of 1.5 μL enzyme/ligand solution, 0.5 micro-seed (1000x 
dilution) and 1.5 μL reservoir solution, seated over a 500 μL reservoir 
using the hanging-drop vapor diffusion method. In order to produce the 
seeds, VAP crystals grown under similar conditions (0.7 M NaCl, 20% 
(w/v) PEG3350 and 0.1 M Tris pH 7.0), were crushed while in the 
original crystallization drop and diluted 1000-fold in the mother liquor. 
A single, triangular crystal with approximate dimension of 130 × 50 ×
20 μm3 was harvested after a three day incubation period at 298 K, 
submerged in cryo-protecting oil (LV CryoOil, MiTeGen, Ithaca, NY) and 
frozen in liquid N2. The crystal diffracted to 2.26 Å (Table 1) and 
allowed for model building and identification of two distinct cyclohex-
ylamine binding sites. 
X-ray diffraction data were collected at the BioMAX beamline at the 
MaxIV laboratory (Lund, Sweden). Data were processed and scaled using 
XDS [39] and AIMLESS [40]. Phases were solved with molecular 
replacement using PHASER within the Phenix interface [41,42], using 
the previously solved crystal structure of native VAP (PDB: 3E2D) [31] 
as the reference model. Refinement was carried out in PHENIX.REFINE 
[43], and manual model building performed in Coot [44]. The final, 
refined structure was validated using MolProbity [45] and the data was 
analyzed in Xtriage (Phenix) [42]. Simulated annealing (SA) Fo-Fc omit 
map for bound ligands were calculated in Phenix and images of the 
models were drawn in PyMOL [46]. Data collection, refinement and 
validation statistics can be seen in Table 1. 
3. Results 
3.1. Cyclohexylamine is a non-competitive inhibitor of VAP 
Fig. 1a shows the concentration dependence of p-nitrophenyl phos-
phate (pNPP) hydrolysis at pH 9.8, which is the pH optimum of the 
enzyme, either using the disodium salt or the bis(cyclohexylamine) salt. 
Inhibition was observed at substrate concentrations above 1 mM using 
the bis(cyclohexylamine) salt, but was not observed with the disodium 
salt. This suggested that the inhibitory effect was due to the cyclohex-
ylamine counterion. The inhibition at pH 9.8 remained unchanged by 
adding 0.5 M NaCl (Fig. 1a). 
At pH 8.0 (Fig. 1b), enzyme activity was more effectively inhibited 
by cyclohexylamine without added NaCl, being reduced to ca. 25% of 
the calculated maximum activity at 6 mM pNPP (equivalent to 12 mM 
cyclohexylamine). The addition of 0.5 M NaCl alleviated the inhibition 
to the level observed at pH 9.8, where no effect of salt was observed 
(Fig. 1a). 
To confirm that inhibition was due to cyclohexylamine, we also 
prepared the stock solution of disodium pNPP with 2 M equivalents of 
cyclohexylamine added, before serial dilution (Fig. 1c). The results were 
practically identical, indicating that cyclohexylamine is the inhibitory 
molecule, rather than a contaminating species. Furthermore, using two 
different batches of bis(cyclohexylamine) pNPP gave identical inhibi-
tory results (data not shown). 
Fig. 2 shows additional experiments using p-nitrophenyl phosphate 
disodium as substrate that confirms cyclohexylamine as a non- 
competitive inhibitor of VAP. A Lineweaver-Burk plot of VAP activity 
at pH 9.8 (Fig. 2b) made from the progress curves (2a) showed a 
decrease in Vmax with increasing inhibitor concentration with the 
regression lines intercepting the x-axis in one point. The unchanged Km 
value indicated a non-competitive inhibition. The Km of 195 ± 4 μM (n 
= 3) obtained here compared well with the previously published value 
of 194 ± 30 μM [32]. At pH 8.0, the lines intercepted the x-axis slightly 
above the y-axis, which could indicate a change in conformation of the 
enzyme in either the ES or ESI states at pH 8.0 compared to pH 9.8 
(Fig. 2d), making the inhibitor binding site non-equivalent to the sub-
strate binding-site. We also tested a mixed model inhibitor analysis that 
gives the factor α as the ratio of the equilibrium constant for EI formation 
(Ki) and for ESI formation (αKi). The α-factor was 1.4 and 1.2 for pH 8.0 
and 9.8, respectively, indicating a mostly non-competitive type of 
interaction (Fig. 2a and c). 
When Vmax as determined at pH 9.8 was plotted against enzyme 
concentration (Fig. 2e), either measured with a substrate solution con-
taining 50 mM cyclohexylamine, or without the inhibitor, the lines 
intersected at the origin, which is consistent with a non-competitive 
inhibition [47]. The inhibition was immediately reversible upon 
dilution. 
Fig. 3a shows the activity of VAP when measured with a constant 
pNPP disodium concentration (2 mM) in the presence of increasing 
concentrations of cyclohexylamine up to 400 mM at pH 9.8. From 
Fig. 3a, the IC50 value was 35.7 mM at 50% of the maximum inhibition 
obtained here (14% residual activity being still left) [37] and 45.3 mM if 
the scaling of inhibition was taken from zero. As mentioned above, the 
relationship Ki = IC50 [38] holds for non-competitive inhibition. 
A considerable amount of chloride accompanies the necessary pre- 
titration of cyclohexylamine with HCl in order to maintain the correct 
Table 1 
VAP co-crystallized with cyclohexylamine. Data collection, refinement and 
validation statistics. Statistics for the highest resolution shell are shown in 
parenthesis.  
Data collection  
Wavelength (energy) 0.9184 Å (13.5 keV) 
Space group P21 
Unit cell parameters a = 76.92 Å, b = 85.27 Å, c = 84.79 Å 
α = β = 90.0◦ , γ = 113.5◦
Resolution range 29.43–2.26 (2.38–2.26) 
Observed reflections 345308 (19763) 
Unique reflections 50781 (3040) 
Multiplicity 6.8 (6.5) 
Completeness (%) 99.0 (94.5) 
Mean I/σ(I) 13.0 (2.5) 
Wilson B-factor 37.78 
Rmerge (%)a 9.4 (67.1) 
Refinement 
Reflections used in refinement 46417 (4301) 
Rworkb 0.160 (0.198) 
Rfreec 0.205 (0.253) 
RMSD (bonds) 0.003 
RMSD (angles) 0.58 
Asymmetric unit contents 




Protein residues 1004 
Average B-factors (Å2) 








Rotamer outliers (%) 0.36 
Cβ outliers 0 
Clash score 2.82 
MolProbity score 1.07 (100th percentiled) 




, where Ii(hkl) is the ith observation of 
reflection hkl and <I(hkl)> < I(hkl) > is the weighted average intensity for all 
observations of reflection hkl. 
b Rwork = Σ|Fobs − Fcalc|ΣFobs, where Fobs and Fcalc are observed and calculated 
reflections, respectively. 
c Rfree value was calculated as Rwork, using only an unrefined, randomly 
chosen subset of reflection data (4.35%) that were excluded from refinement. 
d For structures of comparable resolution (N = 8894, 2.265 Å ± 0.25 Å). 
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pH in all samples. Previous results have shown that the activation of VAP 
caused by ionic strength is specific for the anion and plateaus at around 
0.5 M at pH 9.8, but goes above 1.0 M at pH 8.0 [36]. This causes a 
complication, since a considerable amount of chloride is added with the 
cyclohexylamine (roughly equimolar in concentration). Thus, the chlo-
ride and the inhibitor have an opposing effect on the enzyme activity 
(through independent mechanisms), complicating the determination of 
inhibitor binding potency. We could approximate the activation by 
chloride and correct for the anionic activation at pH 8.0 using eq. (2) 
shown in Materials and methods. Using this approximation, we derived 
a similar result as in Fig. 3a with slightly lower IC50 value of 27.9 mM at 
50% of the maximum inhibition (i.e. 20% residual activity). The addi-
tion of 0.5 M NaCl was shown (Fig. 3b) to decrease the potency of the 
inhibitor resulting in an increase in IC50 to 46.7 mM at 50% of the 
maximum inhibition obtained (i.e. 15% residual activity). 
3.2. Structural details of cyclohexylamine binding to VAP by x-ray 
crystallography 
The VAP-CHA complex crystallized in the primitive P21 space group, 
and the asymmetric unit of the crystal consisted of a single VAP dimer 
(Table 1; Fig. 4). The enzyme contained the reaction product, inorganic 
phosphate (Pi), bound in both active sites as the non-covalent enzyme 
product (E•P) intermediate. Pi was not present in the crystallization 
medium and must, therefore, have remained bound to the enzyme 
through expression and purification. The cyclohexylamine bound to 
VAP in two distinctive sites on each subunit, one in proximity of the 
substrate binding site, and the other close to the dimer interface. The 
overall structure of the enzyme was similar to the previously solved 
crystal structure of VAP (PDB: 3E2D) [31], with a Cα-RMSD of 0.407 Å 
and identical active site metal coordination. However, two magnesium 
ions, not observed in the original crystal structure, were found bound to 
each subunit in the new crystal structure. One was bound on the dimer 
interface of the protein (depicted green in Fig. 4), forming a bridge 
between the two subunits, and the other was bound on the edge of the 
central α/β-domain (depicted red in Fig. 4). Both ions were penta-
coordinated in a trigonal bipyramid geometry and are identically posi-
tioned to the additional magnesium ions found in the highly 
homologous Halomonas sp. alkaline phosphatase [48]. The buried sol-
vent accessible surface area at the dimer interface was increased 
compared to the previously solved wild-type crystal structure. The 
number of hydrogen bonds increased from 54 to 61, whereas the number 
of salt bridges remained the same, being four in both structures. 
Fig. 5a and b detail the binding position of cyclohexylamine with a 
protonated amine group in the active site of VAP’s two subunits, 
whereas 5c is a schematic made in LigPlot with maximum donor and 
acceptor hydrogen bond distances set at 3.5 Å. A charge-charge inter-
action was formed by cyclohexylamine with the inorganic phosphate. 
Further hydrogen bonds extended from the positive charge of cyclo-
hexylamine through water connecting with His116, Arg129, and 
Tyr441. Additional binding came from hydrophobic packing against 
Trp274 and His277. Fig. 5a and b also show the pivotal Arg129 that has 
a major role in binding the phosphate ligand in all APs, and may 
modulate its binding affinity by structural fluctuations. Interestingly, a 
hydrogen bonding interaction through water to Tyr325 in the other 
subunit was noted. Fig. 5d shows how the cyclohexylamine filled the 
entrance tunnel to the binding site of inorganic phosphate in VAP, and 
thereby, might retard product release, but also allow the binding of the 
organic part of the substrate alongside. The binding of the ligand in both 
active sites was confirmed by the SA Fo-Fc omit map (Fig. 5a and b). 
Interestingly, the observed occupancy of the ligand seemed to be higher 
in subunit B, resulting in disruption of the active site hydrogen bonding 
network and displacement of Tyr423. 
Fig. 6 illustrates the peripheral binding position of cyclohexylamine 
on the surface near the dimer interface located around 20 Å from the 
nucleophilic Ser65. The C-terminal of the protein folds to form two 
Fig. 1. VAP activity with two different p-nitrophenyl phosphate salts as a 
substrate. (a) VAP activity was assayed either with the disodium (open circles) 
or the cyclohexylamine (closed symbols) salts of p-nitrophenyl phosphate 
(pNPP) at pH 9.8 without added NaCl (closed circles) and with the addition of 
0.5 M NaCl (red closed squares). (b) Same conditions with same data denotation 
as in (a) but measured at pH 8.0. (c) The result of adding 2 mol of cyclohex-
ylamine to each mole of disodium pNPP (open circles) compared with results 
obtained with cyclohexylamine salt of pNPP alone at the same concentration of 
pNPP. The figure shows results from a representative experiment performed in 
triplicate. The effective concentration of cyclohexylamine was twice that pre-
sented in the figures due to bis-form of the pNPP-salt. The dotted line is a 
calculated fit to the Michaelis-Menten equation using the apparent Km calcu-
lated for the concentration range 0–0.5 mM in each case. (For interpretation of 
the references to color in this figure legend, the reader is referred to the Web 
version of this article.) 
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α-helices (number 24 and 26 in the sequence) and an interconnecting 
γ-turn preceding a short β-strand (number 25 in sequence). Overall, 
residues 483–496 of this motif constitute the binding site. The binding 
was symmetrical in both subunits and the ligand was bound via hy-
drophobic packing against Pro483, Val484, Lys486, Met488, Glu492 
and Tyr496. A chloride ion bound to Lys486 was positioned 3.9 Å from 
the ligand’s ammonium group, further contributing to binding (Fig. 6a). 
It was 6.9 Å away to the newfound dimer interface magnesium ion 
(Fig. 6b). Fig. 6c shows that the interactions were to a great extent hy-
drophobic in nature. 
3.3. Effect of cyclohexylamine on other APs and variants of VAP 
The inhibitory effect of cyclohexylamine on three other APs, from 
E. coli, calf intestines and an Antarctic bacterium (TAB5), was also 
tested. The two cold-active APs were similarly inhibited by cyclohex-
ylamine, whereas the enzymes from E. coli (ECAP) or calf intestines were 
less sensitive to the inhibitory effect (Fig. 3). VAP and TAB5 from an 
Antarctic bacterium [49] are both members of the AP subfamily with a 
Trp in the position numbered 274 in VAP, instead of His (in mammalian 
APs) or Lys 328 in ECAP. As Fig. 3 shows, the cold-active APs were more 
sensitive to inhibition by cyclohexylamine compared with the more 
heat-tolerant variants. Fig. 5 showed how cyclohexylamine forms pri-
mary interactions with Trp274 in VAP. Therefore, we decided to test the 
binding of cyclohexylamine to VAP variants, where Trp274 was 
exchanged for a neutral alanine or a positively charged residue, either 
histidine or lysine. A positive charge would be expected to reduce 
binding affinity for the positively charged ligand. The IC50 (the con-
centration needed to reduce the initial activity by one half, but leaving 
about 20% in residual activity in all cases) was 179 ± 27 (n = 5) with 
W274A, 188 ± 26 mM (n = 6) with W274K and 187 ± 10 mM (n = 3) 
with W274H. Compared with the wild-type value of 45.3 mM, all these 
values are considerably higher, indicating lower binding affinity. 
Fig. 2. The effect of pH on the type of inhibition of VAP by cyclohexylamine. (a) VAP activity was measured with disodium pNPP at pH 9.8 (a, b) and pH 8.0 (c, 
d) with varying concentrations of cyclohexylamine as shown. Global mixed inhibition analysis (a, c) and Lineweaver-Burk reciprocal analysis (b, d) were performed 
to evaluate type of inhibition. (e) Vmax is plotted as a function of enzyme concentration without cyclohexylamine (black circles) or with 50 mM inhibitor (black 
squares) using 2 mM pNPP disodium as substrate. n = 3 from a representative experiment. 
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4. Discussion 
4.1. Inhibitory effects of cyclohexylamine 
The inhibition of an alkaline phosphatase by cyclohexylamine has 
not been previously reported. When VAP activity was tested using pNPP 
disodium, no inhibition was observed, confirming that the inhibition 
was due to cyclohexylamine. Both the kcat and Km of VAP are very pH- 
dependent over the range compared here (pH 8.0 and pH 9.8). At pH 
8.0, the pNPP substrate is fully negatively ionized (pK2 = 5.60 [1]) and 
the cyclohexylamine fully protonated. At pH 9.8, the cyclohexylamine 
should be 85% protonated. Thus, the difference observed in the extent of 
the inhibition at pH 8.0 (Ki = 27.9 mM) compared with pH 9.8 (Ki =
35.7 mM) must have its root in changing properties of the enzyme, 
involving changes in the charge-state of binding residues, and/or 
conformational shifts with effects on geometry and electrostatic fields. 
Cyclohexylamine is a weak base (pKa = 10.63) and it was necessary 
to pre-titrate the inhibitor to the assay’s pH with HCl prior to use in 
order to maintain constant pH. This added about 95% of the inhibitor’s 
molarity in chloride ions. Previous studies have shown that NaCl has a 
stabilizing effect on the enzyme structure and facilitates catalysis [36]. 
This presented some experimental complications to using activity as a 
measure of the inhibitor binding efficacy. As the salt effect on VAP has 
been shown to peak at 0.5 M NaCl at pH 9.8 [36], this concentration was 
added to the buffers to cancel out the effect of the salt brought in by low 
amount of cyclohexylamine on kinetic measurements (Fig. 1). At pH 8.0, 
however, the salt is effective beyond 1 M NaCl in increasing kcat. We 
approximated the effect of chloride in that case by a correction constant 
derived from previous observation for chloride activation under same 
assay conditions [36]. This correction method could have caused the 
slight deviation seen from pure non-competitive inhibition in Fig. 2b 
and d . By adding salt, we shifted the inhibition at pH 8.0 to values 
comparable to those at pH 9.8, but adding salt did not affect the con-
centration dependence (Km) at pH 9.8 much. The fact that a total of 900 
mM of chloride ions was present when 400 mM cyclohexylamine was 
tested in the presence of 500 mM NaCl may offer an explanation as to 
why cyclohexylamine maximally produced 86% inhibition (Fig. 3). 
Since the cyclohexylamine is largely protonated under the test condi-
tions, the NaCl could be interfering with ionic interactions between the 
inhibitor and the enzyme. One might speculate with reference to a 
half-of-site reaction mechanism [50] that there are two populations of 
enzyme molecules and the inhibitor only binds strongly to one of the two 
subunits at a time, and cannot fully prevent the other active site from 
catalyzing the reaction. Another suggestion would be that the EI (or ESI) 
form of the enzyme was not fully inactive, but promoted catalysis at a 
much reduced turnover rate. 
4.2. X-ray crystal structure of cyclohexylamine bound to VAP 
APs are sensitive to inhibition by compounds of various structures, 
the most potent inhibitors being effective in the sub-micromolar range 
[51]. The structure of VAP in the co-crystal state reported here was 
almost identical to the previously solved wild-type structure (PDB: 
3E2D), with a Cα RMSD of 0.407 Å. The sulfate anion present in the 
earlier VAP crystal from the crystallization medium was replaced by an 
inorganic phosphate ion in the present case. Some of the rotamers 
observed for active site residues were not identical in the two subunits, 
and/or deviated from that of the previously published crystal structure 
for wild-type VAP. Tyr423 took on two rotameric forms in subunit B, 
where the occupancy of the ligand seemed higher compared to subunit A 
that showed only one rotamer (Fig. 5a and b). Presumably, this was due 
to rearrangements in the active site hydrogen bonding network of each 
monomer, caused by the binding of the inhibitor. By comparison with 
the earlier wild-type crystal structure, where the nucleophilic Ser65 took 
on two rotamer positions, only one rotamer was observed here (Fig. 5). 
Presumably, this rotamer corresponds to the protonated form of the 
nucleophile which is bound via hydrogen bonding to one of the mag-
nesium coordinating water molecules, and the magnesium coordinating 
Thr118 and Asp12. 
Cyclohexylamine was bound to VAP in direct coordination with the 
reaction product which is inorganic phosphate (Fig. 5), and it was also 
found bound close to the dimer interface (Fig. 6). The active site ligand 
binding was in large part coordinated through charge-charge in-
teractions between the ammonium cation of the inhibitor and the bound 
reaction product (Pi). The protonation state of both Pi and cyclohexyl-
amine cannot be confirmed, but the phosphate is likely fully deproto-
nated as a result of the numerous surrounding cations. Decreased 
inhibition at the higher pH of 9.8 in comparison to pH 8.0 was likely due 
to the lessened protonation of cyclohexylamine and a loss of the positive 
charge interacting with a fully anionic Pi. The decreased inhibition at pH 
9.8 could likewise occur as a result of decreased affinity of the alkaline 
conformer towards the inhibitor due to conformational changes that 
VAP is thought to undergo at alkaline pH [36]. 
In non-competitive inhibition, it is generally assumed that in order 
for the enzyme-inhibitor complex to form, the inhibitor must bind at a 
site other than the active site [52]. Therefore, finding the 
non-competitive inhibitor bound close to where the phosphate binds in 
the active site of the enzyme was quite surprising. Active site binding of 
Fig. 3. The effect of cyclohexylamine on APs from different organisms. (a) 
Activity was measured with 2 mM p-nitrophenyl phosphate disodium at pH 9.8 
and 25 ◦C in a 100 mM CAPS buffer containing 500 mM NaCl. For VAP, a Ki 
value of 45.3 mM and a maximum inhibition of 86% was observed. VAP (cir-
cles); TAB5 AP (triangle pointing down); E. coli AP (rectangle) and calf intes-
tinal AP (triangle pointing up). (b) VAP was measured in a similar way as in (a), 
but at pH 8.0 in a 100 mM Tris buffer, with and without the addition of NaCl. n 
= 3 from a representative experiment. 
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non-competitive inhibitors can occur in the context of an isomechanism 
of catalysis. An isomechanism refers to a mechanism where the enzyme 
binds the substrate in one conformational state but releases the product 
in another, and to reinitiate catalysis it must converge back to the sub-
strate binding form upon product release. In isomechanismic [53] 
enzymes, binding of the inhibitor in the active site of the product 
releasing conformer does not directly compete with the substrate for 
binding and can result in non-competitive inhibition [54,55]. APs 
catalyze the hydrolysis of phosphomonoesters via a bi-bi ping-pong 
mechanism (Scheme 1). We have indicated two structural forms of VAP 
Fig. 4. VAP co-crystallized with cyclohexylamine 
shows two binding sites per subunit in the overall 
structure. The asymmetric unit of the crystal was a 
single VAP dimer with four cyclohexylamine mole-
cules bound shown as blue space-filling models and 
the two subunits in olive ands orange, respectively. 
The zinc ions are shown as grey spheres and magne-
sium ions in the active sites and at the interface as 
dark green spheres. The phosphate ion bound in the 
active sites of the enzyme is shown as red and orange 
sticks. Additionally, the magnesium ion found at the 
surface is shown in red with ligands (For interpreta-
tion of the references to color in this figure legend, 
the reader is referred to the Web version of this 
article).   
Fig. 5. Binding of cyclohexylamine in the 
active sites of the two VAP subunits. (a) The 
binding of the ligand in the active site of mono-
mer A, and (b) in monomer B, with polar contacts 
(<3.5 Å) shown as yellow dashes. The cyclo-
hexylamine is shown as magenta and blue sticks, 
water molecules forming polar contacts with the 
ligand are shown as red spheres and inorganic 
phosphate as yellow and orange sticks. The 
active site magnesium ion is colored as a green 
sphere and the two zinc ions as grey spheres. The 
final refined 2Fo-Fc map (grey) is contoured at 1σ 
and the SA Fo-Fc omit map (green) at 5.5σ. (c) A 
ligand plot drawn using LigPlot [65] further 
illustrating the binding in monomer A to 
acceptors/donors within 3.5 Å. (d) A view of the 
substrate entry channel of the active site, 
showing inorganic phosphate being eclipsed by 
the bound cyclohexylamine. The sliced surface is 
colored according to the YRB coloring scheme 
[66] (For interpretation of the references to color 
in this figure legend, the reader is referred to the 
Web version of this article).   
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by a star, in line with an isomechanismic character and some previously 
suggested models implicating a structural change in the general reaction 
pathway for APs [50,56,57]. 
At alkaline pH, the rate limiting step of AP catalysis is the dissocia-
tion of bound inorganic phosphate (Pi) [58], and the reaction mecha-
nism has previously been postulated to be of isoenzymatic nature, 
involving conformational changes between high and low affinity states 
to facilitate product release and substrate binding [57]. As mentioned 
above, the presence of Pi in the active sites of the enzyme indicates that 
this crystal structure represents the non-covalent enzyme-product (E∙Pi) 
complex. The structural analysis showed that active site binding of 
cyclohexylamine was in large part coordinated directly by the bound 
phosphate ion via charge-charge interactions. Therefore, the active site 
binding of cyclohexylamine possibly occurs only in the enzyme-product 
complex with the bound phosphate as a necessary co-inhibitor. This 
could result both in retardation of product release, as the inhibitor 
blocks the path of the product out of the active site (Fig. 5c), or in 
impairment of a conformational change needed for product release. 
Cyclohexylamine did not affect substrate binding, as the Km value 
remained unchanged, and therefore, does likely not bind to the free 
enzyme species in the same manner as p-nitrophenyl phosphate. How-
ever, the binding together of cyclohexylamine and the substrate in the 
active site of the free enzyme species, to form a ternary 
enzyme-substrate-inhibitor complex, is a possibility. 
The second binding site of the inhibitor (Fig. 6) was found on the 
surface of the protein, in proximity to the dimer interface, in a small 
peripheral hydrophobic binding pocket 20 Å from the nucleophilic 
Ser65. The binding occurred almost exclusively through hydrophobic 
packing, with the addition of a coordinating chloride ion. When the 
inhibition of VAP by cyclohexylamine was measured at pH 8.0, with or 
without 0.5 M NaCl, little variation was observed (Fig. 3b). Therefore, 
the binding of cyclohexylamine seems not to depend on the prior 
binding of chloride. As noted above, inter-subunit interactions are 
important for maintaining the active conformation of the AP dimer and 
subunit communication are likely to be involved in the catalytic cycle 
[32,36]. Cyclohexylamine binding distally from the active site could 
affect inter-subunit interactions, or conformational changes involved in 
catalysis. However, the binding interactions appeared weaker than in 
the active site due to lack of the ionic contribution and changes in res-
idue 274 in the active site affected affinity for the inhibitor. 
Mammalian alkaline phosphatases are allosteric enzymes which are 
inhibited in an uncompetitive manner by L-amino acids. This likely 
serves a downregulating function in vivo [59,60]. A crystal structure of 
the human placental AP (PLAP) with bound L-phenylalanine (L-Phe) 
revealed two distinct binding sites of the inhibitor involving the covalent 
phosphoenzyme intermediate [61]. Firstly, L-Phe bound in a small, 
hydrophobic and peripheral surface site on the α/β-domain of the 
(caption on next column) 
Fig. 6. Binding of cyclohexylamine in the surface site of the A subunit in 
VAP. Cyclohexylamine bound on the surface of the VAP dimer in an identical 
manner on both subunits. (a) Coordination is mostly via hydrophobic in-
teractions with Pro483, Val484, Lys486, Met488, Glu492 and Tyr496. Addi-
tional coordination came from a chloride ion positioned 3.5 Å from the 
ammonium group of the ligand, which was further coordinated by Lys486 via a 
distance of 3.9 Å. Furthermore, the chloride ion was observed in proximity (6.9 
Å) to the newfound dimer interface magnesium ion. The magnesium ion was 
pentacoordinated by the backbone carbonyl groups of Ala45(A), Gln46(A), 
Gly48(A) and Ser485(B) in trigonal bipyramid geometry. The binding was 
symmetrical on both sides of the dimer. The bound cyclohexylamine is shown 
as magenta and blue sticks, and selected water molecules are shown as red 
spheres. The refined 2mFo-Fc map (grey) is contoured at 1σ and the SA Fo-Fc 
omit map (green) at 4.5σ. (b) The surface of the protein colored according to 
the YRB coloring scheme to illustrate the hydrophobic nature of the binding 
pocket. (c) A ligand plot illustrating the hydrophobic interactions of the ligand 
(For interpretation of the references to color in this figure legend, the reader is 
referred to the Web version of this article). 
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protein, located 26 Å from the nucleophilic Ser92 in the active site 
(Ser65 in VAP). Secondly, L-Phe was bound in the active sites of the 
enzyme. The active site binding occurred in large part via charge-charge 
interactions between the amino group of L-Phe and the phosphoserine 
reaction intermediate, in addition to hydrophobic interactions with 
Tyr367 (homologous to Tyr325 in VAP). The binding mode of L-Phe is 
highly similar to the active-site binding of cyclohexylamine to VAP 
(Fig. 7). Recent results from our group have shown that L-Phe is in fact a 
mixed-type inhibitor (α∕=1) of VAP, with a Ki of 54.2 mM at pH 9.8 
(Unpublished results; B. Ásgeirsson and G. Jónsdóttir). This is in a 
similar range to the value observed for cyclohexylamine here (45.3 
mM). Additionally, the inhibitory effect of L-Phe decreased in VAP 
mutants W274A, W274K and W274H, to a similar extent as observed 
here with cyclohexylamine, further supporting the similarities between 
cyclohexylamine and L-Phe binding. Tyr325 in VAP (Tyr367 in PLAP) is 
a highly conserved AP residue, as a tyrosine residue is found in the 
equivalent position in all known APs except for ECAP [62]. This residue 
reaches into the active site of the other monomer and has previously 
been postulated to be important for inter-subunit interactions [31]. 
Therefore, the binding of cyclohexylamine to VAP could possibly 
suggest a regulatory role of Tyr325. Further work would be required to 
confirm its regulatory role in VAP. 
4.3. Inhibitory effects on AP variants and VAP homologs 
We previously reported that the kinetic effect of replacing W274 in 
the VAP’s active site with lysine found in ECAP (K274) was to reduce the 
overall reaction rate (kcat) to 15–30% of wild-type with a slight reduc-
tion in substrate affinity under similar hydrolyzing conditions as used 
here [33,34]. For the W274H variant, previous results indicated an 
unchanged Km value, but 50% reduction in kcat [34]. The prominent 
interaction with Trp274 in the active site as summarized by the LigPlot 
scheme (Fig. 5c) was supported with experimental results as a decrease 
in the inhibitory effect was observed upon replacing Trp274 via 
site-directed mutagenesis with alanine, lysine or histidine. 
The inhibition by cyclohexylamine of other APs was also evaluated in 
this work. The analysis showed that AP from the Antarctic TAB5 bac-
terium was inhibited to a similar extend as VAP, but ECAP and calf- 
intestinal alkaline phosphatase (CAP) were not. Whereas the structure 
of CAP is not known, the crystal structures of both ECAP and TAB5 AP 
have been solved [63,64]. Most of the residues mentioned above for 
inhibitor binding to VAP (Trp274, Tyr325 and His277) are found in the 
active site of TAB5 AP (Trp260, Tyr325 and His263) with the exception 
of Tyr441, being in an insert sequence in VAP. Thus, a similar binding 
mode could be expected in TAB5 AP as in VAP. In ECAP, only the zinc 
ligand His331 is shared, being homologous to His277 of VAP. 
Database linking and accession numbers 
IUBMB Enzyme Nomenclature: EC 3.1.3.1. 
Protein Data Bank: X-ray crystal structure of Vibrio alkaline phos-
phatase with the non-competitive inhibitor cyclohexylamine (PDB ID: 
6T26). 
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Scheme 1. Reaction mechanism of VAP indicating two structural states of the 
dimer, E and E* 
Fig. 7. Active site binding of L-phenylalanine to human placental AP re-
sembles that of cyclohexylamine to VAP. L-Phe is an uncompetitive inhibitor 
of human placental alkaline phosphatase (PLAP) (PDB: 1 ZEF, [61]). Shown are 
the active sites of PLAP (magenta sticks) and VAP (yellow sticks) aligned. All 
residues within 4 Å of the two ligands in the alignment are shown, as are metal 
coordinating residues. L-Phe (shown in green) binds only in the active site of 
the covalent phosphoenzyme intermediate in PLAP (in the form of 
phosphoserine-92; Sep92). L-Phe is mainly bound via hydrophobic interactions 
with the inter-subunit Tyr367 (homologous to Tyr325 in VAP). The amino 
group of L-Phe is seen in electrostatic interactions with the phosphoserine. 
Similarly, the binding of cyclohexylamine (light blue sticks) to VAP occurs only 
in the presence of bound inorganic phosphate. All L-Phe binding residues of 
PLAP are conserved in VAP, and a similar binding mode of L-Phe could be 
expected in VAP. The two active site zinc ions are shown as grey spheres and 
the magnesium ion as a green sphere. (For interpretation of the references to 
color in this figure legend, the reader is referred to the Web version of 
this article.) 
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